Georgia CTSA MSCR Graduate Leads Successful Study for Microbiota Treatments Addressing Antibiotic Resistance
Many patients in long-term acute care hospitals (LTACHs) have intestinal multidrug-resistant organism colonization. Despite risk for infection and transmission, no FDA-approved therapies exist to reduce it. To assess the safety and feasibility of fecal microbiota transplantation (FMT), Michael Woodworth, MD, MSCR, Emory, led a non-randomized trial at a LTACH in Atlanta. Results showed FMT was well tolerated with no related serious adverse events.